Project Grant R21CA309945
Award Date 5/13/26
Completion Date 4/30/28
Dollars Obligated $431K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10021, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $716,521 to Sloan-Kettering Institute for Cancer Research on August 25, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cells for treating small cell lung cancer (SCLC). The research initiative addresses a critical clinical need, as SCLC currently demonstrates...
- Federal Grant Award Summary The National Cancer Institute awarded The Leland Stanford Junior University a $584,521 Project Grant on August 8, 2025, under the Cancer Treatment Research program (CFDA 93.395) to investigate subclonal determinants of radiation response in soft tissue sarcomas. The research will deliver three primary products: (1) identification and validation of epigenetic changes, including DNA methylation and chromatin accessibility alterations, that confer radioresistance to...
- Federal Project Grant Award Summary The National Cancer Institute awarded $730,398 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, with a completion date of March 31, 2031. This project grant supports research into the emergence of tumor regenerative states during neoadjuvant therapy in locally advanced rectal cancer (LARC). The research aims to determine whether resistance to total neoadjuvant therapy (TNT)—which...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $640,466 Project Grant to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026 through May 31, 2031. This five-year initiative focuses on developing a novel class of covalent protein radiopharmaceuticals for targeted radionuclide therapy in cancer treatment. The project involves designing and genetically incorporating latent...
- Federal Grant Award Summary The National Cancer Institute awarded $727,732 to Sloan-Kettering Institute for Cancer Research on June 3, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct a Phase IB/II clinical trial investigating combination therapy for dedifferentiated liposarcoma (DDLS). The primary deliverable is a clinical trial evaluating the efficacy and safety of palbociclib combined with the MEK inhibitor mirdametinib in patients with progressive DDLS, with an...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $730,398 to Sloan-Kettering Institute for Cancer Research through the Cancer Treatment Research program (CFDA 93.395) on September 1, 2025, for a five-year project period concluding August 31, 2030. This Project Grant supports research and development activities designed to advance novel treatment approaches for rectal cancer, with emphasis on organ preservation strategies that minimize patient morbidity. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a $700,838 Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) beginning April 1, 2026 and concluding March 31, 2031. This award supports the development and optimization of advanced magnetic resonance (MR) imaging and treatment planning methodologies to enable functional avoidance stereotactic body radiation therapy (FA-SBRT) for...